Calliditas intends to commercialize Nefecon for IgA nephropathy on a standalone basis in the United States and most likely through partnerships in other regions.

For further information or to discuss new opportunities, please contact:

Business enquiries

Please email our business development team for any business enquiries.


Mail address

Calliditas Therapeutics AB
PO Box 70351
SE-10724 Stockholm, Sweden